Status:

COMPLETED

Study to Evaluate the Safety/Tolerability, PK and PD After Intravenous DWJ1521 Administration in Healthy Volunteers

Lead Sponsor:

Daewoong Pharmaceutical Co. LTD.

Conditions:

Healthy Volunteers

Eligibility:

All Genders

19-50 years

Phase:

PHASE1

Brief Summary

A randomized, double-blind, placebo-controlled, multiple-dose clinical trial to evaluate the safety/tolerability and pharmacokinetics, and pharmacodynamics after intravenous DWP14012 injection in heal...

Eligibility Criteria

Inclusion

  • Healthy adults aged ≥ 19 and ≤ 50 years at screening
  • Subjects with a body weight of ≥ 55.0 kg to ≤ 90.0 kg with a body mass index (BMI) of ≥ 18.0 and ≤ 28.0 at screening
  • ☞ BMI(kg/m2) = weight (kg) / {Height (m)}2
  • Subjects who have given written consent on voluntary decision of participation prior to the screening procedure after being fully informed of and completely understanding this study
  • Subjects eligible to participate in the study at the discretion of the investigator by physical examination, laboratory tests, investigator questioning, etc.

Exclusion

  • Present or prior history of clinically significant hepatic, renal, nervous system, immune, respiratory, and endocrine diseases, hematologic and oncologic diseases, cardiovascular diseases, or mental diseases
  • Gastrointestinal diseases (gastric ulcer, gastritis, gastric cramps, gastroesophageal reflux, Crohn's disease, etc.) that may affect the safety and pharmacokinetic evaluation results of investigational drugs and those with a history of gastrointestinal surgery (except for appendix surgery and hernia surgery alone).
  • Helicobacter pylori positive.

Key Trial Info

Start Date :

January 10 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 6 2022

Estimated Enrollment :

33 Patients enrolled

Trial Details

Trial ID

NCT06508645

Start Date

January 10 2022

End Date

April 6 2022

Last Update

July 18 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Seoul-National University Hospital

Seoul, South Korea, 03080

Study to Evaluate the Safety/Tolerability, PK and PD After Intravenous DWJ1521 Administration in Healthy Volunteers | DecenTrialz